Autosomal recessive retinitis pigmentosa (arRP) has recently been associated with mutations in a novel gene, EYS, which is a major gene for this disease. All published mutations so far are based on conventional PCR and are not adequate to identify midsized DNA rearrangements. This study was conducted to establish the prevalence of copy-number variations (CNVs) in the EYS gene in a cohort of arRP patients, including individuals in whom only one pathogenic change was detected by PCR-based sequencing. METHODS. A multiple ligation-dependent probe amplification (MLPA) was used for the molecular genetic analyses of CNVs by a novel EYS-specific kit. PCR-based direct sequencing was used in families where a pathogenic deletion or duplication was identified in one allele. Bioinformatics analyses was undertaken to study the effect of the mutations on protein structure and function. RESULTS. Six novel pathogenic CNVs were identified. Also, the presence of four midsized deletions was confirmed in patients previously identified. Midsized genomic rearrangements in EYS are disease causing in ϳ4% of the families with no reported mutations and constitute the second pathogenic variation in ϳ15% of cases where a mutation has been detected by direct sequencing. CONCLUSIONS. This is the first report of a systematic CNV screening of EYS gene in a cohort of arRP patients. Results suggest that midsized genomic rearrangements in EYS gene would be a common event in the appearance of RP phenotype. This disease can be inherited as an autosomal dominant, autosomal recessive, or an X-linked trait. All genes identified to date are believed to account for roughly 50% of all retinal dystrophy cases. 3 The autosomal recessive form of RP is the commonest worldwide, accounting for approximately 50%-60% of cases.
previously identified. Midsized genomic rearrangements in EYS are disease causing in ϳ4% of the families with no reported mutations and constitute the second pathogenic variation in ϳ15% of cases where a mutation has been detected by direct sequencing. CONCLUSIONS. This is the first report of a systematic CNV screening of EYS gene in a cohort of arRP patients. Results suggest that midsized genomic rearrangements in EYS gene would be a common event in the appearance of RP phenotype. An efficient and cost-effective strategy validating a novel MLPA kit as a complementary diagnostic method for EYS pathogenic evaluation has been demonstrated. (Invest Ophthalmol Vis Sci. 2011;52:5625-5631) DOI:10.1167/iovs. R etinitis pigmentosa (RP [MIM 268000]) is a generic name for inherited retinal dystrophies with loss of photoreceptor cells and retinal pigment deposits at midperiphery of the retina, which are visible on fundus examination. RP is characterized by primary degeneration of the rod photoreceptors followed by secondary degeneration of cones. This degeneration initially causes night blindness, followed by constriction of the visual field, abnormal color vision, and progressive loss of visual acuity in the later life. 1 Prevalence of RP is approximately 1/4000 births with over 1 million individuals affected worldwide. 2 This disease can be inherited as an autosomal dominant, autosomal recessive, or an X-linked trait. All genes identified to date are believed to account for roughly 50% of all retinal dystrophy cases. 3 The autosomal recessive form of RP is the commonest worldwide, accounting for approximately 50%-60% of cases. 2 To date, a total of 32 genes have so far been implicated in autosomal recessive RP (arRP; http://www.sph.uth.tm.edu/Retnet/). However, all together these genes appear to account for only 35%-45% of total arRP cases. 2 Recently we have identified a new gene, EYS, corresponding to the RP25 locus, 4 encoding an ortholog of Drosophila spacemaker (SPAM), as a commonly mutated gene in arRP. 5 Spanning over 2 Mb within the RP25 locus (6q12.1-6q15), EYS is the largest eye-specific gene identified so far. The longest EYS isoform encodes a protein of 3165 amino acids. Immunohistochemical data reveal its localization in the outer segment of the photoreceptor layer. Although its role in visual function has not yet been established, the evolutionary data, the new extensive bioinformatic analyses, and the known function of the drosophila ortholog support a structural role for this new protein contributing to the human retinal morphogenesis and architecture. 6, 7 The initial identification of six independent mutations in our cohort of Spanish families linked to RP25, together with the presence of different mutations in arRP families from different origins, supports EYS as the first major gene for arRP. 5, [7] [8] [9] [10] [11] [12] The identification of EYS causative mutation is important for clinical diagnosis, predictions of the clinical course of the disease, genetic counseling, and future gene-targeted therapies. Majority of mutations identified so far include missense, nonsense, microdeletions and insertions, and putative pathogenic changes in the 5ЈUTR region. However, no duplications and few midsized deletions affecting EYS (to a few Kb) have been reported to date. This low rate of identified copy-number variations (CNVs) leading to arRP may be explained by the fact that the techniques usually used, based on conventional PCR, are not adequate to identify such rearrangements. Due to the technical difficulties in determining gene dosage in this size range, it is possible that the proportion of mutations that are deletions or duplications has been underreported, and the presence of midsized rearrangements undetectable by PCR-based procedures would also explain the failure to detect the second mutant allele in a significant number of arRP families. 7, 9, 10 In fact, only three studies have investigated midsized insertions/deletions in EYS using comparative genomic hybridization (CGH), CNVs analysis (Genechip 6.0 Affymetrix array; Affymetrix, Santa Clara, CA) and/or self-designed multiple ligation probe-dependent amplification (MLPA) probes. 5, 7, 9 Thus, the availability of a rapid accurate molecular diagnostic complementary method to identify midsized rearrangements could enhance acute clinical management as well as genetic counseling. Here we report the pathogenic implication of EYS CNVs in Spanish and French arRP populations using MLPA. For this purpose we have tested and validated a novel EYS MLPA kit (MRC-Holland, Amsterdam, the Netherlands) in 95 arRP patients, including those where only one pathogenic change had previously been identified by PCR-based direct genomic sequencing. We have identified novel EYS rearrangements in six arRP cases. In addition, we have confirmed the presence of CNVs in four families with midsized deletions previously detected by CGH and self-designed MLPA.
MATERIALS AND METHODS

Subjects and Clinical Data
The study cohort comprises 95 Spanish and French unrelated patients affected by arRP, comprising 78 Spanish and 17 French patients. A full ophthalmic examination was performed, and the clinical diagnosis was based on visual acuity, fundus photography, computerized testing of central and peripheral visual fields, and electroretinography (ERG) findings. RP was defined as bilateral visual loss, initial hemeralopy, restriction of visual field, gradual increased bone spicule pigmentation and decrease of visual acuity, attenuation of retinal vessels, reduced or undetectable electroretinogram (ERG), and waxy disc pallor. The pattern of inheritance in all participating patients was diagnosed based on the pedigree The eight reference probes were used as controls. structure, characterized by more than one affected member and the nonaffected progenitors in arRP families.
Globally, our cohort included 71 arRP patients with no known mutation, 20 patients with a single mutation detected by PCR-based direct sequencing, and four positive controls for CNVs. Also three negative controls were included for technique normalization.
The Spanish cohort included five carriers of a pathogenic variant, previously identified in a heterozygote state by PCR-based direct sequencing. 7 (Table 1) . Additionally, two midsized EYS deletion carriers previously identified were included as positive controls. 5 ( Table 1 ). The French cohort was composed of 15 patients with a previously identified heterozygous EYS mutation, 9 (Table 1 ) and included two other homozygous individuals with midsized deletions as positive controls for the validation of MLPA.
In addition, available samples of probands' family members were tested for cosegregation studies. An informed consent was obtained from all participants for clinical and molecular genetic studies. The study conformed to the tenets of the Declaration of Helsinki.
MLPA Analysis
Gene dosage variation in EYS were analyzed by MLPA technology using a novel MLPA kit especially designed for EYS. The P328-X1 EYS MLPA Kit (MRC-Holland, Amsterdam, the Netherlands) contains 50 MLPA probes designed to detect alterations in the copy number of one or more exons in the EYS gene that can be implicated in arRP. In addition, this kit also includes eight reference control probes that hybridize to sequences in different regions of the genome ( Table 2 ). The MLPA † There are no probes to detect possible deletions in exon 10. ‡ There are no probes to detect possible deletions in exon 32.
reaction was performed in a thermal cycler (Biometra TGRADIENT; Biometra, Goettingen, Germany), following the manufacturer's recommendations (http://www.mlpa.com). Capillary electrophoresis analysis was performed in an analyzer (3730 DNA analyzer; Applied Biosystems, Foster City, CA), and commercially available software (GeneMarker v. 1.75; Softgenetics, State College, PA) was used for data analysis. We normalized the samples comparing the peak heights of patients versus controls. In addition, we included positive controls harboring three homozygous arRP EYS deletion patients (F115, F735, and RP5) and one patient with a heterozygous deletion (RP73). 5, 9 The MLPA analysis criteria were as follows: (1) 
PCR-Based Direct Genomic Sequencing of EYS
To find the second pathogenic variation in those families where a new deletion/duplication was identified in one of the alleles by MLPA, we sequenced EYS by PCR-based direct sequencing. Moreover, these results helped to discard the presence of allelic variants in the probe target sequences that may have led to false positive results. PCR and sequencing procedures follows the protocols previously described in Barrágan et al. 7 .
To evaluate the pathogenicity of the novel variants, software (Netphos2.1; NetPhos2.0 Server, http://www.cbs.dtu.dk/services/NetPhos/) was used to predict the alteration in phosphorylation. 13 All the changes were assigned a nucleotide number starting at the first translation base of EYS isoform according to the GenBank Reference Sequence Version FJ416331; GI: 212675237; Transcript Reference Sequence: NM_001142800.1 (ensemble entry ENST00000503581).
RESULTS
Validation of EYS P328-X1 MLPA Kit
Using a novel MLPA P328-X1 Kit, we first confirmed the presence of four midsized deletions in patients previously identified by CGH and self-designed MLPA. 5, 9 They consisted of three midsized homozygous deletions and one patient with a heterozygous deletion affecting exons 15-19, 32-33, and 12, in control families RP5, F115, F735, and RP73, respectively (Fig. 1, Table 3 ).
Identification of Novel Very Likely Pathogenic CNVs
MLPA analyses led to the identification of six novel EYS rearrangements. The sequence variants were designated in accordance with the Human Genome Variation Society recommendations (http://www.hgvs.org/mutnomen/) ( Table 1 ).
In the RP1 family, we found a heterozygous duplication of exons 3 and 4 in the affected individual (Fig. 2) . It is the first FIGURE 2. MLPA profiles for control individuals (red) and for arRP patients with heterozygous deletions (blue). For the RP patients a decrease of dosage was observed for EYS exons 3, 4, 12, 16, 17, 19, 33 and introns 4, 12 , and 17, indicating a heterozygous deletion. In the case of RP1 family, an increment for the dosage of EYS exons 3 and 4 indicates a heterozygous duplication for these exons. time a duplication in EYS is reported.
Direct sequencing of this patient's DNA revealed a c.8897GϾA (p.Gly2945Glu) as the second pathogenic change (Fig. 3) . The amino acid substitution locates in an EGF domain of SPAM. Turning to evolutionary conservation, this glycine is present in this position in EYS homologues previously reported by our group. 7 The substitution of glycine to glutamate in position 2945 introduces an acidic polarity in a previously hydrophobic position. In addition, this change is not tolerated according to computational predictions, since it implies the loss of one phosphorylation site (NetPhos2.1).
In the RP3 family index patient, we found a novel homozygous deletion including exons 12 and 13. The segregation analysis in the family was consistent with the recessive pattern of inheritance (Table 4) .
Index patients in F225, F618, and F360 families had been previously described as carrying truncating mutations identified by PCR-based direct sequencing (Table 1) . After MLPA screening, we have identified three midsized heterozygous deletions, affecting exons 3-4, 9, and 33, respectively, as the second pathogenic change in the EYS gene. In addition, family segregation in available members (F618 and F360) , supported the pathogenic nature of those mutations ( Table 4) .
The screening of the index patient from family RP2 revealed a heterozygous deletion involving exons 16 -19 . However, in this case, PCR-based direct sequencing failed to identify the second mutant allele.
DISCUSSION
Molecular diagnosis of RP is a challenging task given the important genetic heterogeneity of these groups of diseases. EYS represents a major arRP gene, as can be appreciated in view of the high number of EYS mutations detected by PCR-based direct genomic sequencing reported in different arRP patients and the diverse ethnic origins of these families. 5, [7] [8] [9] [10] [11] [12] However, mutations due to midsized deletions (a few kilobases) in EYS have seldom been reported.
Typical screening protocols using conventional PCR-based sequencing methods are only able to detect small duplications/ deletions (a few base pairs) and are dependent on the size of the amplified fragment in one reaction (ϳ1 Kb maximum) On the other hand, cytogenetic techniques can exclusively detect large alterations ranging several megabases in size. None of the The major advantages of MLPA are ease of use, high throughput, and being cheaper than other techniques such as real-time PCR or CGH. The MLPA method allows the detection of midsized insertions/deletions ranging from the probe size (ϳ40 bases) to a few Kb (depending on the length of tested gene) in a large number of individuals within a short time period. This technique is being used extensively in the molecular diagnosis of a wide range of diseases caused by deletions or duplications of one or more exons in specific genes. 14, 15 In this case the novel MLPA kit has a maximum detection range of ϳ2 Mb, corresponding to the EYS genomic interval.
First, to evaluate the novel MLPA kit, we confirmed the presence of four midsized deletions in patients previously identified by CGH and self-designed MLPA. 5, 9 Therefore, validation of the novel kit used was successfully achieved.
As a result of the MLPA screening for CNVs, we have identified six novel EYS rearrangements in six out of 91 unrelated patients with arRP (see Supplementary Fig. S2 , http://www.iovs.org/lookup/ suppl/doi:10.1167/iovs.11-7292/-/DCSupplemental). Majority of identified CNVs are predicted to generate a frameshift leading to a premature stop codon, and probably, most of these altered mRNA transcripts will be degraded through nonsense mediated decay. 16 In the case of F228, RP1, and F360 families, we cannot predict the putative protein effect of the mutation, since the extent of the CNVs is unknown, due to the absence of probes for the adjacent exons (see Supplementary Fig. S3 , http://www.iovs.org/ lookup/suppl/doi:10.1167/iovs.11-7292/-/DCSupplemental). It is very likely that they would lead to a frame shift generating a novel stop codon, or the loss/gain of a significant portion of the protein, rich in important functional domains. In both cases the outcome would be sufficient to be pathogenic. The identification of different CNVs in EYS in three out of 71 families with no known mutations, reveals a probable mutation frequency of ϳ4% of the cases, indicating that this kind of genomic rearrangements in EYS gene would be a significant possibility in the appearance of the RP phenotype. Also, three out of 20 families carrying a mutation in one allele detected by PCR-based direct sequencing were found to have a rearrangement in the second mutated allele in EYS. This indicates that, at least, 15% of families with one heterozygous change identified by PCR-based direct sequencing would be a carrier of a midsized pathogenic deletion/insertion. However, it is still possible that some of the 17 remaining cases with only one pathogenic mutation also carry deletions/duplications affecting the EYS gene, as the current P328-X1 probemix does not contain probes for exons 2, 5, 6, 10, 18, and 32. Therefore, the P328-X1 probemix must be updated to improve both the accuracy and detection rate of rearrangements in EYS by MLPA.
In summary, this is the first report of a systematic CNV screening of EYS gene in a large cohort of arRP patients. Our results show that midsized genomic rearrangements in EYS are a common event in the development of the RP phenotype. They are responsible for the disease in about 4% (3/71) of the families with no reported mutations and constitute the second pathogenic variation in approximately 15% (3/20) of cases where a mutation has been detected by PCR-based direct sequencing. Globally, ϳ5% (5/91) of all arRP families included in this study bear a pair of EYS mutations as the likely cause of the disease, and ϳ1% (1/91) present a heterozygous mutation. Of the mutations, ϳ7% (6/91) are midsized rearrangements, whereas ϳ2% (2/91) are single-nucleotide substitutions, and ϳ2% (2/91) are other variants detectable by PCR-based sequencing (Fig. 4) . Determination of the underlying genetic defects in a patient is a prerequisite for gene or mutation-specific therapy; thus, this knowledge is crucial for future therapies design. Therefore, the development of efficient and cost-effective strategies to detect mutation is mandatory. We have demonstrated that MLPA is an efficient and cost-effective strategy as a complementary diagnostic method for EYS pathogenic evaluation in arRP families.
